Connor Clark & Lunn Investment Management Ltd. Grows Position in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)

Connor Clark & Lunn Investment Management Ltd. lifted its stake in shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) by 64.7% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 137,031 shares of the company's stock after buying an additional 53,809 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned about 0.22% of Corvus Pharmaceuticals worth $724,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Samlyn Capital LLC increased its holdings in Corvus Pharmaceuticals by 160.7% in the second quarter. Samlyn Capital LLC now owns 6,123,021 shares of the company's stock worth $11,144,000 after purchasing an additional 3,774,658 shares in the last quarter. Point72 Asset Management L.P. acquired a new position in Corvus Pharmaceuticals during the second quarter worth $10,855,000. Vanguard Group Inc. increased its holdings in Corvus Pharmaceuticals by 10.6% during the 1st quarter. Vanguard Group Inc. now owns 1,493,357 shares of the company's stock worth $2,658,000 after purchasing an additional 142,724 shares in the last quarter. Marshall Wace LLP bought a new position in Corvus Pharmaceuticals during the 2nd quarter valued at $136,000. Finally, Oppenheimer & Co. Inc. bought a new position in shares of Corvus Pharmaceuticals during the third quarter valued at about $89,000. 46.64% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

CRVS has been the subject of several research reports. StockNews.com downgraded Corvus Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Thursday, October 31st. Mizuho upgraded shares of Corvus Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, October 22nd. LADENBURG THALM/SH SH raised their price objective on Corvus Pharmaceuticals from $12.00 to $21.00 and gave the company a "buy" rating in a report on Monday, September 16th. Finally, Oppenheimer increased their target price on Corvus Pharmaceuticals from $8.00 to $14.00 and gave the company an "outperform" rating in a report on Wednesday, November 13th. One investment analyst has rated the stock with a sell rating, three have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Corvus Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus price target of $12.83.

Corvus Pharmaceuticals Stock Performance

CRVS traded down $0.33 during trading on Friday, hitting $9.09. 321,732 shares of the stock were exchanged, compared to its average volume of 381,959. The firm has a 50 day simple moving average of $7.50 and a 200 day simple moving average of $4.48. The firm has a market cap of $584.12 million, a price-to-earnings ratio of -10.05 and a beta of 1.05. Corvus Pharmaceuticals, Inc. has a 1 year low of $1.30 and a 1 year high of $10.00.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.